Andreas Jurgeit, Ph.D.
Board Member, Indi Molecular
Investment Director, M Ventures
Dr. Andreas Jurgeit is Investment Director on the Life Sciences team at M Ventures (Merck Ventures BV, Amsterdam, the Netherlands, a subsidiary of Merck KGaA, Darmstadt Germany known as M Ventures in the United States and Canada), the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany.
He previously held positions as investment manager at the Zurich-based VC Redalpine, active across various industries with investments in life sciences and ICT, and business development at the Swiss-based Redbiotec where he was instrumental to the trade-sale of its subsidiary RedVax to Pfizer in 2014.
Dr. Jurgeit received his MSc in Molecular Biology from the University of Innsbruck (Austria) and his Ph.D. in Cell Biology and Molecular Virology from the University of Zurich (Switzerland). While in Switzerland he worked with the Menlo Park-based 3V Biosciences on the discovery of host factor-based antiviral strategies and drug development by applying Systems Biology approaches. Dr. Jurgeit lectures on Business Strategy (IFJ, ETH Zurich) and advises academic institutes on the commercialization of research findings.